Evidence map›Paper›PMID 22791108›Full record

ReviewCurrent diabetes reports2012

Continuous glucose monitoring in children and adolescents.

Robert Henry Slover

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Robert Henry SloverBarbara Davis Center and The Children's Hospital Colorado, University of Colorado, Aurora, CO 80045, USA. robert.slover@ucdenver.edu

Funding

Coordinating Center: Glucose Sensors in Type I DiabetesU01HD041890 · NICHD · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI BECK, ROY W · 2001 to 2006
$4.1M
NICHD NIH HHS U01 HD041890
6 · The paper itself

Abstract

Continuing glucose monitoring (CGM) is a relatively new and rapidly developing technology that shows promise for the future management of type 1 diabetes. When used with near-daily frequency, it has a significant effect on improvement of glucose metabolism as measured by HbA1C and reduction of hypoglycemia. It appears to be safe and actually reduces both DKA and severe hypoglycemia. Early studies indicate that it should be cost effective.

Indexed as

AdolescentBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansHypoglycemiaMaleGlycated Hemoglobin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.